CD274 and triple-negative breast carcinoma: Immunotherapy with anti-programmed cell death ligand 1 (anti-PD-L1, atezolizumab) was recently approved by the Food and Drug Administration (FDA) for the indication of PD-L1-positive metastatic triple negative breast cancer (TNBC) [1, 2].